Figure 6.
In Vivo Activity of Cytokine-Reactive mAbs
(A) mAb administered i.p. at day 0, and human IL17F administered i.d. on days 1, 3, 6, and 8. Ear thickness measured on all days (prior to cytokine injection) except day 5.
(B) As in (A), but with human IL32γ administered i.d.
(C) anti-IL22-specific mAb injected i.p. into 9-week mice prior to and during IMQ treatment. Efficacy measured by Psoriasis Area and Severity Index (PASI).
Significance calculated by two-way ANOVA, with ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, and ∗∗∗∗p ≤ 0.0001. Error bars denote SEM.